Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
Rhea-AI Summary
Recursion (NASDAQ: RXRX) reported that its Board Compensation Committee approved inducement restricted stock unit (RSU) awards on May 26, 2026, covering 2,991,840 class A shares for 33 new employees under its 2024 Inducement Equity Incentive Plan.
RSUs vest over multiple years, subject to continued employment.
AI-generated analysis. Not financial advice.
Positive
- Equity awards covering 2,991,840 shares granted to attract 33 new hires
- Multi-year RSU vesting schedule designed to support employee retention
Negative
- Inducement RSU awards represent potential dilution of up to 2,991,840 shares
Key Figures
Market Reality Check
Peers on Argus
Peers showed mixed moves (e.g., APGE +5.01%, GLPG -2.8%, TVTX -1.21%), while RXRX gained 8.52% with no peers in the momentum scanner, pointing to a stock-specific move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 06 | Earnings and update | Positive | +1.8% | Q1 2026 results, clinical updates, and runway into early 2028. |
| Apr 30 | Board transition | Neutral | -2.0% | Founder to leave board after June 2026, remain strategic advisor. |
| Apr 29 | Earnings date set | Neutral | -3.2% | Announcement of Q1 2026 earnings release and call details. |
| Apr 07 | Investor conferences | Neutral | +1.3% | Planned participation in Needham and Bank of America healthcare conferences. |
| Mar 25 | New CMO appointment | Positive | +0.0% | Appointment of Vicki Goodman, M.D., as incoming Chief Medical Officer. |
Recent company news has more often seen muted or negative price reactions, with only the latest earnings/busines update showing a positive move.
Over the last few months, Recursion reported multiple corporate developments, including Q1 2026 results with cash of $665.2M and runway into early 2028, leadership changes such as a new Chief Medical Officer, and participation in investor conferences. Board transitions and routine scheduling of earnings dates previously saw small negative moves. Compared with these items, the current inducement RSU grants fit into ongoing equity-based compensation and governance activity rather than a major strategic or clinical inflection point.
Market Pulse Summary
This announcement details inducement RSU grants covering 2,991,840 shares to 33 new employees under the 2024 Inducement Equity Incentive Plan, structured with 1/4 initial vesting and 1/16 quarterly thereafter. It reflects ongoing use of equity for talent recruitment under Nasdaq Listing Rule 5635(c)(4). In context of recent earnings, leadership changes, and insider filings, investors may watch how future compensation decisions intersect with cash runway, clinical milestones, and governance developments.
Key Terms
restricted stock unit financial
rsu financial
nasdaq listing rule 5635(c)(4) regulatory
inducement equity incentive plan financial
AI-generated analysis. Not financial advice.
Salt Lake City, UT, May 29, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on May 26, 2026, the Compensation Committee of Recursion's Board of Directors approved the grant of inducement restricted stock unit (RSU) awards covering 2,991,840 shares of its class A common stock in the aggregate to 33 new employees under Recursion's 2024 Inducement Equity Incentive Plan (the “2024 Plan”). Each award was granted as an inducement material to the employee's commencement of employment with Recursion, or a subsidiary of Recursion, pursuant to Nasdaq Listing Rule 5635(c)(4).
Each inducement RSU award will vest as to 1/4th of the shares subject to the award on the first quarterly vesting date on or following the one-year anniversary of the vesting commencement date, and as to 1/16th of the shares on each quarterly vesting date thereafter until the inducement RSU award is fully vested, subject to the inducement RSU award recipient’s continued employment through the company vesting dates. Each inducement RSU award is subject to the terms and conditions of the 2024 Plan and the grant agreements covering the awards.
About Recursion
Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.
Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Montréal, New York, London, and the Oxford area. Learn more at www.recursion.com, or connect on X and LinkedIn.
Media Contact
Media@Recursion.com
Investor Contact
Investor@Recursion.com
Ryan Kelly Recursion Pharmaceuticals ryan.kelly@recursion.com